Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PLD2 | O14939 | 2/20 | 0.41 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biriperone SCHEMBL635469 | 0.76 | DRD3 (1.00) | DRD3 | |
| SCHEMBL11883126 | 0.67 | DRD3 (0.50) | DRD3KDM4EMAPT | |
| SCHEMBL30969330 | 0.66 | ALDH1A1 (0.71) | HDAC1HDAC6KDM4E | |
| SCHEMBL12244114 | 0.65 | KDM4E (0.48) | DRD3KDM4E | |
| SCHEMBL29605727 | 0.65 | CYP1A2 (0.74) | HDAC1HDAC6KDM4E | |
| SCHEMBL19139017 | 0.63 | KDM4E (0.46) | DRD3KDM4E | |
| SCHEMBL10722398 | 0.63 | HPGD (0.67) | HDAC6KDM4EMAPT | |
| SCHEMBL3065071 | 0.62 | ADRA1A (0.45) | DRD3KDM4E | |
| SCHEMBL12727426 | 0.61 | CYP19A1 (0.58) | KDM4EMAPT | |
| SCHEMBL1338592 | 0.61 | CYP19A1 (0.68) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085869-A1 | IMPROVED HYDROGEL FOR DELIVERY OF PHARMACEUTICAL AGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-24 | — | — | WO | disclosed |
| US-12208094-B2 | Extended release, abuse deterrent dosage forms | SpecGx LLC (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240009117-A1 | ENHANCED UPTAKE TRANSMUCOSAL DRUG DELIVERY COMPOSITIONS AND METHODS OF USE | PADAGIS ISRAEL PHARMACEUTICALS LTD. | 2024-01-11 | — | — | US | disclosed |
| EP-3164117-B1 | ABUSE DETERRENT IMMEDIATE RELEASE FORMULATIONS COMPRISING NON-CELLULOSE POLYSACCHARIDES | SpecGx LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11617712-B2 | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides | SpecGx LLC (US) | 2023-04-04 | — | — | US | disclosed |
| US-20230079134-A1 | EXTENDED RELEASE, ABUSE DETERRENT DOSAGE FORMS | SUCAMPO PHARMA AMERICAS LLC | 2023-03-16 | — | — | US | disclosed |
| US-11583493-B2 | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides | SpecGx LLC (US) | 2023-02-21 | — | — | US | disclosed |
| US-11517521-B2 | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides | SpecGx LLC (US) | 2022-12-06 | — | — | US | disclosed |
| US-11478426-B2 | Abuse deterrent immediate release capsule dosage forms | SpecGx LLC (US) | 2022-10-25 | — | — | US | disclosed |
| US-11446293-B2 | Extended release, abuse deterrent dosage forms | SpecGx LLC (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2022098641-A1 | ENHANCED UPTAKE TRANSMUCOSAL DRUG DELIVERY COMPOSITIONS AND METHODS OF USE | PADAGIS ISRAEL PHARMACEUTICALS LTD. (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009117-A1 | ENHANCED UPTAKE TRANSMUCOSAL DRUG DELIVERY COMPOSITIONS AND METHODS OF USE | SLC18A3, SLC10A2, SLC18A1 | DRD3 2835/4885PRMT5 3417/4885WDR77 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.